In the print version of the article listed above, in Table 2, the units for stage II (12–24 weeks) ITCA 650 20→20 mg, ITCA 650 20→60 mg, and Ex-BID/ITCA 650 40 mg and for 0–24 weeks ITCA 650 20→60 m should have been μg. In addition, the units in the sentences “In stage I (week 12), high anti-exenatide antibody titers were observed in 0, 2.1, and 4.5% of subjects treated with 20 and 40 mg/day of ITCA 650 and Ex-BID, respectively” and “In stage II (week 24), high titers were observed in 5.3, 7.0, 7.3, and 10% of subjects receiving 20, 40, 60, and 80 mg/day of ITCA 650, respectively” should have been μg/day. The online version reflects these changes.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See for details.